Open an account

Ovid Therapeutics

OVID · NASDAQ

$2.36+$0.19 (+8.76%)TodayMarket closed ·
Prev close $2.17

About OVID

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Employees
23
Headquarters
New York City, New York
Listed
May 5, 2017
Sector
Health Care
Industry
Biotechnology
Website
ovidrx.com

OVID key statistics

Market cap
460.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.60M
Volume
3.67M
Open price
$2.19
High today
$2.46
Low today
$2.18
52 Week high
$3.11
52 Week low
$1.18

Ovid Therapeutics (OVID) at a glance

As of Oct 20, 2026, Ovid Therapeutics (OVID) shares are priced at $2.36, giving the company a market cap of 460.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.18 and $2.46. The current price is 8.5% above the day's low and 4.1% below its high.

Volume so far is 3.67M shares, above the average of 1.60M shares a day.

Over the past year Ovid Therapeutics has ranged from $1.18 to $3.11, and now sits 61% of the way up that range.

Ovid Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.1234.

The average analyst price target is $6.12, 159.3% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $6.12
Low
$4.04
Now
$2.36
High
$9.45

OVID earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 46.2% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of -$0.208
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.1693
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1394
  4. Q2 FY25: reported -$0.06 per share against an estimate of -$0.1649
  5. Q3 FY25: reported -$0.17 per share against an estimate of -$0.1529
  6. Q4 FY25: reported $0.06 per share against an estimate of -$0.1214
  7. Q1 FY26: reported -$0.12 per share against an estimate of -$0.1227
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.1234

OVID news

  • Press releasePRNewswire

    Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

  • Vandana Singh

    uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts

  • Press releaseBusiness Wire

    Ligand Reports Second Quarter 2024 Financial Results

Similar companies

Companies in the same industry as Ovid Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.